380 related articles for article (PubMed ID: 27685843)
1. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
[TBL] [Abstract][Full Text] [Related]
5. The neuropeptide genes
Misawa K; Mima M; Imai A; Mochizuki D; Misawa Y; Endo S; Ishikawa R; Kanazawa T; Mineta H
Clin Epigenetics; 2018; 10():52. PubMed ID: 29682090
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of galanin receptor 1 in head and neck cancer.
Misawa K; Ueda Y; Kanazawa T; Misawa Y; Jang I; Brenner JC; Ogawa T; Takebayashi S; Grenman RA; Herman JG; Mineta H; Carey TE
Clin Cancer Res; 2008 Dec; 14(23):7604-13. PubMed ID: 19047085
[TBL] [Abstract][Full Text] [Related]
8. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer.
Misawa K; Kanazawa T; Misawa Y; Imai A; Uehara T; Mochizuki D; Endo S; Takahashi G; Mineta H
J Cancer Res Clin Oncol; 2013 May; 139(5):879-89. PubMed ID: 23420374
[TBL] [Abstract][Full Text] [Related]
9. Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
Kostareli E; Hielscher T; Zucknick M; Baboci L; Wichmann G; Holzinger D; Mücke O; Pawlita M; Del Mistro A; Boscolo-Rizzo P; Da Mosto MC; Tirelli G; Plinkert P; Dietz A; Plass C; Weichenhan D; Hess J
Epigenetics; 2016; 11(1):61-73. PubMed ID: 26786582
[TBL] [Abstract][Full Text] [Related]
10. Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.
Kanazawa T; Kommareddi PK; Iwashita T; Kumar B; Misawa K; Misawa Y; Jang I; Nair TS; Iino Y; Carey TE
Clin Cancer Res; 2009 Apr; 15(7):2222-30. PubMed ID: 19276245
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.
Uehara T; Kanazawa T; Mizukami H; Uchibori R; Tsukahara T; Urabe M; Kume A; Misawa K; Carey TE; Suzuki M; Ichimura K; Ozawa K
Cancer Sci; 2014 Jan; 105(1):72-80. PubMed ID: 24168112
[TBL] [Abstract][Full Text] [Related]
12.
Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
[TBL] [Abstract][Full Text] [Related]
13. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma.
Kanazawa T; Misawa K; Carey TE
Expert Opin Ther Targets; 2010 Mar; 14(3):289-302. PubMed ID: 20148716
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
[TBL] [Abstract][Full Text] [Related]
15. Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma.
Weiss D; Stockmann C; Schrödter K; Rudack C
Cell Oncol (Dordr); 2013 Jun; 36(3):213-24. PubMed ID: 23529585
[TBL] [Abstract][Full Text] [Related]
16. Promoter Hypermethylation Profiling Identifies Subtypes of Head and Neck Cancer with Distinct Viral, Environmental, Genetic and Survival Characteristics.
Choudhury JH; Ghosh SK
PLoS One; 2015; 10(6):e0129808. PubMed ID: 26098903
[TBL] [Abstract][Full Text] [Related]
17. The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma.
Sugimoto T; Seki N; Shimizu S; Kikkawa N; Tsukada J; Shimada H; Sasaki K; Hanazawa T; Okamoto Y; Hata A
Genes Chromosomes Cancer; 2009 Feb; 48(2):132-42. PubMed ID: 18973137
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of epigenetic inactivation of vascular endothelial growth factor receptors in head and neck squamous cell carcinoma.
Misawa Y; Misawa K; Kawasaki H; Imai A; Mochizuki D; Ishikawa R; Endo S; Mima M; Kanazawa T; Iwashita T; Mineta H
Tumour Biol; 2017 Jul; 39(7):1010428317711657. PubMed ID: 28718364
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation using 24-gene array in early head and neck cancer: better outcome in oral than in oropharyngeal cancer.
Noorlag R; van Kempen PM; Moelans CB; de Jong R; Blok LE; Koole R; Grolman W; van Diest PJ; van Es RJ; Willems SM
Epigenetics; 2014 Sep; 9(9):1220-7. PubMed ID: 25147921
[TBL] [Abstract][Full Text] [Related]
20. Prostanoid receptor genes confer poor prognosis in head and neck squamous cell carcinoma via epigenetic inactivation.
Misawa K; Mima M; Satoshi Y; Imai A; Mochizuki D; Ishikawa R; Kita J; Yamaguchi Y; Endo S; Misawa Y; Mineta H
J Transl Med; 2020 Jan; 18(1):31. PubMed ID: 31969157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
